142 related articles for article (PubMed ID: 34019742)
21. Primary cutaneous anaplastic large-cell lymphoma with DUSP22-IRF4 rearrangement following insect bites.
Zhang Y; Chen M; Yu Y; Liu X; Liu W; Jiang L; Zhang W
J Cutan Pathol; 2022 Feb; 49(2):187-190. PubMed ID: 34622970
[TBL] [Abstract][Full Text] [Related]
22. Co-occurring rearrangements of
Klairmont MM; Ward N
Leuk Lymphoma; 2022 Feb; 63(2):506-508. PubMed ID: 34612143
[No Abstract] [Full Text] [Related]
23. DUSP22 rearrangement in primary cutaneous T cell lymphoma with features intermediate between mycosis fungoides, anaplastic large-cell lymphoma and lymphomatoid papulosis.
Diaz de la Pinta FJ; Machan S; Manso Alonso R; Carvajal N; Nieves Salgado R; Piris MA; Rodriguez-Pinilla SM
Histopathology; 2022 Jan; 80(2):446-449. PubMed ID: 34252219
[No Abstract] [Full Text] [Related]
24. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing.
Feldman AL; Dogan A; Smith DI; Law ME; Ansell SM; Johnson SH; Porcher JC; Ozsan N; Wieben ED; Eckloff BW; Vasmatzis G
Blood; 2011 Jan; 117(3):915-9. PubMed ID: 21030553
[TBL] [Abstract][Full Text] [Related]
25. Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphoma.
Xing X; Flotte TJ; Law ME; Blahnik AJ; Chng WJ; Huang G; Knudson RA; Ketterling RP; Porcher JC; Ansell SM; Sidhu J; Dogan A; Feldman AL
Appl Immunohistochem Mol Morphol; 2015 Sep; 23(8):580-9. PubMed ID: 25390351
[TBL] [Abstract][Full Text] [Related]
26. Primary effusion anaplastic large cell lymphoma with indolent clinical course and IRF4/DUSP22 rearrangement: a case report expanding the spectrum of effusion-based lymphoma.
Yuan CT; Cheng AL; Hou HA
Virchows Arch; 2023 Mar; 482(3):641-645. PubMed ID: 35984488
[TBL] [Abstract][Full Text] [Related]
27. Constant small-cell changes and variable LEF1 expression in DUSP22-rearranged primary cutaneous anaplastic large-cell lymphoma: Analysis of the repeated biopsies of three patients.
Osakada A; Fujimoto M; Ueshima C; Kaku Y; Nishikori M; Inoue N; Takeuchi K; Haga H
Pathol Int; 2023 Sep; 73(9):456-462. PubMed ID: 37530485
[TBL] [Abstract][Full Text] [Related]
28. Primary cutaneous anaplastic large cell lymphoma with DUSP22-IRF4 rearrangement demonstrating a biphasic histopathologic pattern and a complete natural regression.
Kitajima Y; Yamashina M; Hanamoto M; Shijimaya T; Terai S; Nakamaru S; Makimura K; Inoue N; Takeuchi K; Kiyohara T
J Dermatol; 2022 Sep; 49(9):e309-e310. PubMed ID: 35560037
[No Abstract] [Full Text] [Related]
29. Cutaneous presentation of enteropathy-associated T-cell lymphoma masquerading as a DUSP22-rearranged CD30+ lymphoproliferation.
Bisig B; Cairoli A; Gaide O; Somja J; Bregnard C; Gaulard P; Xerri L; Lefort K; Missiaglia E; Gilliet M; Hohl D; Guenova E; de Leval L
Virchows Arch; 2022 Oct; 481(4):653-657. PubMed ID: 35366115
[TBL] [Abstract][Full Text] [Related]
30. Histopathological features and outcomes of DUSP22 rearrangement in primary cutaneous anaplastic large cell lymphoma: a case report and review of the literature.
Nieto-Benito LM; Parra-Blanco V; Gómez-Navarro Y; Menárguez-Palanca J; Pulido-Pérez A
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):e670-e672. PubMed ID: 34014587
[No Abstract] [Full Text] [Related]
31. Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement.
Magaki S; Satyadev R; Chen Z; Yung KS; Vinters HV; Kinney MC; Said JW
Brain Tumor Pathol; 2022 Jan; 39(1):25-34. PubMed ID: 34791573
[TBL] [Abstract][Full Text] [Related]
32. Anaplastic large cell lymphomas with equivocal DUSP22 FISH results: recommendations for clinical reporting and diagnostic evaluation.
Fadl A; Oishi N; Shi M; Dasari S; Ansell SM; Ketterling RP; Feldman AL
Hum Pathol; 2023 Nov; 141():6-14. PubMed ID: 37633531
[TBL] [Abstract][Full Text] [Related]
33. ALK
Jiang X; Zhou D
Blood; 2018 Apr; 131(15):1764. PubMed ID: 29650733
[No Abstract] [Full Text] [Related]
34. ALK-negative anaplastic large cell lymphoma with
Sibon D; Bisig B; Bonnet C; Poullot E; Bachy E; Cavalieri D; Fataccioli V; Bregnard C; Drieux F; Bruneau J; Lemonnier F; Dupuy A; Bossard C; Parrens M; Bouabdallah K; Ketterer N; Berthod G; Cairoli A; Damaj G; Tournilhac O; Jais JP; Gaulard P; De Leval L
Haematologica; 2023 Jun; 108(6):1590-1603. PubMed ID: 36453105
[TBL] [Abstract][Full Text] [Related]
35. Should treatment of ALK-positive anaplastic large cell lymphoma be stratified according to minimal residual disease?
Rigaud C; Abbas R; Grand D; Minard-Colin V; Aladjidi N; Buchbinder N; Garnier N; Plat G; Couec ML; Duplan M; Lambilliotte A; Schmitt C; Leblanc T; Lamant L; Brugières L
Pediatr Blood Cancer; 2021 Jun; 68(6):e28982. PubMed ID: 33687135
[TBL] [Abstract][Full Text] [Related]
36. Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma.
Wang X; Wu J; Zhang M
Hematology; 2019 Dec; 24(1):440-445. PubMed ID: 31072226
[TBL] [Abstract][Full Text] [Related]
37. Patch/plaque mycosis-fungoides-like presentations of DUSP22-translocated T-cell lymphomas.
Runge JS; Novice ML; Briones N; Williams K; Lowe L; Boyer DF; Wilcox RA; Tejasvi T; Hristov AC
J Cutan Pathol; 2022 Mar; 49(3):299-305. PubMed ID: 34699105
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma.
Rigaud C; Abbou S; Minard-Colin V; Geoerger B; Scoazec JY; Vassal G; Jaff N; Heuberger L; Valteau-Couanet D; Brugieres L
Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29193772
[No Abstract] [Full Text] [Related]
39. Aberrant expression and genetic alteration of c-MYC in anaplastic large cell lymphoma.
Chen Z; Chai F; Xi Y; Zhang H; Xu Y; Zhang Z; Li S; Tian X
J Cancer Res Clin Oncol; 2022 Jan; 148(1):267-278. PubMed ID: 34131801
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis of anaplastic lymphoma kinase-negative anaplastic large cell lymphoma on pleural fluid cytology.
Greenland NY; Lu CM; Cook S; Peng Y
Diagn Cytopathol; 2021 Dec; 49(12):E458-E461. PubMed ID: 34406711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
